# Ketamine in Borderline Personality Disorder

> **NCT03395314** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 22 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03395314
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-15
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-05-06
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** assessment of project in wake of covid-19 related interruptions
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395314, "Ketamine in Borderline Personality Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03395314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*